NCT07677072Recruiting
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 98 (estimated)
- First submitted
- 24 Jun 2026
- Start date
- 15 May 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Diseases
- Osteoporosis
- NCT number
- NCT07677072
What you commit to
- Study type: Observational
- Planned participants: 98
- From 15 May 2026 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major surgery within the previous 6 months
- Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents
Other illness
- Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders)
- Active infection or acute inflammatory disease
- Neurological or muscular disorders that may significantly affect muscle function
Other
- Premenopausal women
- Inability to comply with study procedures and assessments
- Refusal or inability to provide written informed consent
Who the study is looking for
- Female sex
- Age 45 years or older
- Postmenopausal status
- Attendance at the Physical Medicine and Rehabilitation outpatient clinic
- Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation
- Ability and willingness to provide written informed consent
Age in the registry: 45 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey Coordinator of this site? Confirm its status | Küçükçekmece | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.